“The required dosage for many advanced therapies is very low—sometimes 0.5 mL or less. Getting the highest yield from your batch is essential, since each additional dosage treats another patient. Current and future customers will be able to serve their patients better thanks to the new Dynamic Peristaltic Pump,” explains Chris Procyshyn, CEO and co-founder of Vanrx.
Vanrx CEO Chris Procyshyn writes in the latest issue of The Medicine Maker how adopting closed, automated aseptic processing systems is a crucial step to bring 21st century therapies to patients.
G-CON Manufacturing and Vanrx Pharmasystems today announced the companies are working together to offer the Microcell POD, the first and only turnkey facility for aseptic filling of advanced therapies.
When looking for a new fill-finish solution for its gene therapy manufacturing operations, CDMO FUJIFILM Diosynth Biotechnologies turned to isolator technology offered by Vanrx Pharmasystems. Thomas Page, Vice President, Engineering and Asset Development, was interviewed by the editor of The Medicine Maker about their experience working with Vanrx.
For the second year in a row, Deloitte has presented Vanrx Pharmasystems with its Technology Fast 50 and North American Technology Fast 500 awards in recognition of rapid revenue growth, entrepreneurial spirit and bold innovation.
Is “gloveless isolator” the best term to describe a fully closed system for aseptic filling? Jim Akers said no in the PDA Letter, so here's our thinking about what to call this new generation of flexible filling systems.